



GAMP Good Practice Guide

**A Risk-Based
Approach to Testing
of GxP Systems**

Second Edition

A leader in providing
Computer Systems
Implementation,
Validation and
Quality Assurance
Services.



CQV (An Azzur Group Company) provides consulting services to the Life Sciences Industry. We offer system integration, compliance and validation services within the Quality Assurance, Laboratory, Clinical, IT/IM, Business Processes, Manufacturing, Operations, and R&D settings to our pharmaceutical, biotechnology and medical device clients.

SERVICES AVAILABLE

- RISK-BASED LAB RELOCATION
- COMPUTER SYSTEMS VALIDATION
- INSTRUMENT IQ/OQ/PQ SERVICES
- LIFE CYCLE DOCUMENTATION
- LIMS SYSTEM QUALIFICATION
- IT INFRASTRUCTURE
- PROJECT MANAGEMENT

With a depth of expertise in all facets of the system life cycle we are able to assist our clients within any phase to reach their goals of running a lean, efficient operation.

“...to achieve success?”

CQV (An Azzur Group Company) takes a holistic approach when working with our clients to provide the best service possible. We work hand in hand with each client to achieve success by ensuring that all goals are met and safe and effective products are delivered.





GAMP Good Practice Guide

A Risk-Based Approach to Testing of GxP Systems

Second Edition

Disclaimer:

This Guide focuses on functional, structural, and performance testing of GxP systems and is intended to assist regulated organizations and suppliers to work together to ensure sufficient test coverage to guarantee fitness for intended use, while minimizing any duplication of effort. ISPE cannot ensure and does not warrant that a system managed in accordance with this Guide will be acceptable to regulatory authorities. Further, this Guide does not replace the need for hiring professional engineers or technicians.

Limitation of Liability

In no event shall ISPE or any of its affiliates, or the officers, directors, employees, members, or agents of each of them, or the authors, be liable for any damages of any kind, including without limitation any special, incidental, indirect, or consequential damages, whether or not advised of the possibility of such damages, and on any theory of liability whatsoever, arising out of or in connection with the use of this information.

© Copyright ISPE 2012. All rights reserved.

No part of this document may be reproduced or copied in any form or by any means – graphic, electronic, or mechanical, including photocopying, taping, or information storage and retrieval systems – without written permission of ISPE.

All trademarks used are acknowledged.

ISBN 978-1-936379-51-4

Preface

This document, the ISPE GAMP® Good Practice Guide: A Risk-Based Approach to Testing of GxP Systems, represents a revision of the first edition, ISPE GAMP® GPG – Testing and is intended as a supplement to ISPE GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems. This Guide focuses on functional, structural, and performance testing. It has been updated to align with the concepts and terminology of GAMP® 5 and regulatory and industry developments which focus attention on patient safety, product quality, and data integrity.

The ISPE GAMP® Community of Practice Document Task Team was asked to revise this Guide. The team consisted of representatives from regulated organizations, contract research organizations, suppliers of pharmaceutical systems and equipment, and consultants.

Acknowledgements

The production of the ISPE GAMP® Good Practice Guide: Risk-Based Approach to Testing of GxP Systems was initiated by the Testing Task Team at the request of the GAMP® Council.

The following members of the GAMP® Community of Practice (COP) Testing Task Team worked on one or more sections of this Guide and volunteered countless hours to attend meetings and review the many drafts. The members committed to, and achieved, a challenging timescale for this substantial revision and their exceptional efforts are much appreciated.

Chairs

| | | |
|-----------------|---------------------------|----------------|
| Karen Ashworth | Karen Ashworth Consulting | United Kingdom |
| Charlie Wakeham | Pall Life Sciences | United Kingdom |

Task Team Members

| | | |
|------------------------|--|----------------|
| Kevin Ashley | Siemens Healthcare Diagnostics | United Kingdom |
| Karen Ashworth | Karen Ashworth Consulting | United Kingdom |
| Roger Buchanan | Lilly UK | United Kingdom |
| Jonathan Davey | Provalidus Ltd. | United Kingdom |
| Stephen Dawson | Eden Biodesign Ltd. | United Kingdom |
| Angille K. Heintzman | NHS Blood and Transplant | United Kingdom |
| Daniel G. Mewborn | Eli Lilly and Company | USA |
| Daniel Montgomery | Covance, Inc. | USA |
| Radha Ramesh | TCS | USA |
| Genni Sanders | Systematicity | United Kingdom |
| George Smerdon | Industrial Technology Systems Ltd. (ITS) | United Kingdom |
| Paul Smith | Agilent Technologies | United Kingdom |
| Kimberly Stanton | QPharma, Inc. | USA |
| David Stokes | Business & Decision Life Sciences | United Kingdom |
| Thanabalan Subramanian | GE Healthcare | United Kingdom |
| Matthew Theobald | Three Circles | United Kingdom |
| Steve Tinson | Scitech | United Kingdom |
| Simon Topham | Napp Pharmaceuticals Limited | United Kingdom |
| Anders Vidstrup | NNIT A/S | Denmark |
| Linda Waddick | Eli Lilly and Company | USA |
| Charlie Wakeham | Pall Life Sciences | United Kingdom |

Within this highly professional and committed team, special thanks are due to David Stokes, Kimberly Stanton, and Steve Tinson for their expertise in innovative technologies and methodologies, and their dedication in formulating the guidance in these areas.

Contributing Members

The following contributors are members from the GAMP® COP US Automation SIG and GAMP® COP DACH Automation SIG. David Stokes coordinated the work of the Automation SIGs and integrated that work into the Guide as Appendix T11.

| | | |
|-----------------------|----------------------------|---------|
| Peter Brandstetter | Arcondis GmbH | Austria |
| Konstantin Clevermann | IDS Scheer Consulting GmbH | Germany |
| Thierry Dietrich | Arcondis | Germany |
| Srinivas Gopanapalli | Cognizant | USA |

| | | |
|--------------------------|------------------------------------|-------------|
| Andreas Hengstberger | Nycomed Austria GmbH | Austria |
| Bernhard Kausler | ITQ GmbH | Germany |
| Oliver Kieckhöfel | BTConsult GmbH | Germany |
| Stefan Münch (DACH Lead) | Rockwell Automation Solutions GmbH | Germany |
| Radha Ramesh (US Lead) | TCS | USA |
| Shweta Rangarajan | Celgene Corp. | USA |
| Ernst-Reiner Schäfer | Abacon GmbH | Switzerland |
| Jason R. Tepfenhardt | Genilogix | USA |

The GAMP® Testing Task Team would like to acknowledge the support of their direct management and companies in this endeavor.

Particular thanks go to the GAMP® COP Editorial Review Board for their review and comment:

| | | |
|---------------------|------------------------------|----------------|
| Winnie Cappucci | Bayer Healthcare (retired) | USA |
| Chris Clark (Chair) | Napp Pharmaceuticals Limited | United Kingdom |
| Gail Evans | ISPE | United Kingdom |
| Colin Jones | Conformity Limited | United Kingdom |
| Randy Perez | Novartis | USA |
| Sion Wyn | Conformity Limited | United Kingdom |

The Leaders of the GAMP® Testing Task Team wish to thank GAMP® Council, GAMP® Europe Steering Committee, and the Guidance Documents Executive Committee (GDEC) for their contributions and commitment throughout the production of this Guide.



**Connecting a World of
Pharmaceutical Knowledge**

ISPE Headquarters

600 N. Westshore Blvd., Suite 900, Tampa, Florida 33609 USA
Tel: +1-813-960-2105, Fax: +1-813-264-2816

ISPE Asia Pacific Office

73 Bukit Timah Road, #04-01 Rex House, Singapore 229832
Tel: +65-6496-5502, Fax: +65-6336-6449

ISPE China Office

Suite 2302, Wise Logic International Center
No. 66 North Shan Xi Road, Shanghai, China 200041
Tel +86-21-5116-0265, Fax +86-21-5116-0260

ISPE European Office

Avenue de Tervueren, 300, B-1150 Brussels, Belgium
Tel: +32-2-743-4422, Fax: +32-2-743-1550

www.ISPE.org

Table of Contents

| | | |
|----------|---|-----------|
| 1 | Introduction | 9 |
| 1.1 | Overview | 9 |
| 1.2 | Purpose..... | 9 |
| 1.3 | Scope..... | 10 |
| 1.4 | Benefits | 12 |
| 1.5 | Objectives | 12 |
| 1.6 | Structure of this Guide | 13 |
| 2 | Key Concepts | 15 |
| 2.1 | Product and Process Understanding | 15 |
| 2.2 | Life Cycle Approach within a QMS..... | 16 |
| 2.3 | Scalable Life Cycle Activities | 17 |
| 2.4 | Science-Based Quality Risk Management..... | 18 |
| 2.5 | Leveraging Supplier Involvement..... | 19 |
| 3 | Regulated Organization and Supplier Relationship | 23 |
| 3.1 | Introduction | 23 |
| 3.2 | The Supply Chain | 24 |
| 3.3 | Quality Risk Management..... | 25 |
| 3.4 | Supplier Assessment | 26 |
| 3.5 | Leveraging Supplier Testing..... | 28 |
| 3.6 | Determining Appropriate Test Evidence..... | 31 |
| 3.7 | Ongoing Support..... | 32 |
| 3.8 | Commercial Issues | 32 |
| 4 | Appendix T1 – Test Practices | 35 |
| 4.1 | Introduction | 35 |
| 4.2 | Test Policies | 35 |
| 4.3 | Types of Verification..... | 37 |
| 4.4 | Determination of the Scope of Testing..... | 58 |
| 5 | Appendix T2 – Test Planning and Test Management | 61 |
| 5.1 | Introduction | 61 |
| 5.2 | Test Plan or Strategy..... | 61 |
| 5.3 | Test Metrics..... | 81 |
| 5.4 | Automated Tools for Planning and Management..... | 88 |
| 6 | Appendix T3 – Test Specifications, Cases, and Scripts..... | 91 |
| 6.1 | Test Specifications or Test Protocols | 91 |
| 6.2 | Test Cases and Test Scripts..... | 92 |
| 6.3 | Example Test Step Classification Scheme..... | 99 |
| 6.4 | Example Test Scripts and Cases | 100 |

| | | |
|-----------|--|------------|
| 7 | Appendix T4 – Test Environments | 105 |
| 7.1 | Introduction | 105 |
| 7.2 | Hardware Environment | 107 |
| 7.3 | Test Software | 108 |
| 7.4 | Test Data Sets..... | 109 |
| 7.5 | Test User Accounts | 111 |
| 7.6 | Test Documentation | 111 |
| 7.7 | Managing Test Environments..... | 111 |
| 7.8 | Automated Testing | 114 |
| 7.9 | Non-Linear Software Development Methods | 114 |
| 8 | Appendix T5 – Testing Execution..... | 115 |
| 8.1 | Introduction | 115 |
| 8.2 | Test Pre-Requisites..... | 115 |
| 8.3 | Test Execution..... | 115 |
| 9 | Appendix T6 – Test Results Recording and Reviewing | 119 |
| 9.1 | Test Evidence..... | 119 |
| 9.2 | Test Record Integrity | 120 |
| 9.3 | Post Execution Review | 121 |
| 9.4 | Test Evidence for Packaged Systems..... | 122 |
| 10 | Appendix T7 – Test Reporting and System Handover | 125 |
| 10.1 | Test Reports..... | 125 |
| 10.2 | Leveraging Supplier Testing..... | 126 |
| 10.3 | Determination of Residual Risk..... | 127 |
| 10.4 | Formal Handover and Release | 127 |
| 11 | Appendix T8 – Testing in the Operational Phase..... | 131 |
| 11.1 | Types of Change..... | 131 |
| 11.2 | Test Planning and Test Management | 133 |
| 11.3 | Testing Changes | 134 |
| 11.4 | Releasing a Change | 138 |
| 12 | Appendix T9 – Testing as Part of Data Management..... | 141 |
| 12.1 | Introduction | 141 |
| 12.2 | Data Migration..... | 141 |
| 12.3 | Data Verification..... | 142 |
| 12.4 | Manual Data Migration and Data Verification..... | 145 |
| 12.5 | Automated Data Migration and Data Verification | 146 |
| 12.6 | Data Management in the Operational Phase..... | 149 |
| 13 | Appendix T10 – Testing in Non-Linear Software Development Methods | 155 |
| 13.1 | Introduction | 155 |
| 13.2 | Non-Linear Software Development Life Cycles | 155 |
| 13.3 | Prototyping..... | 157 |
| 13.4 | Non-Linear Software Development Risk Scenarios..... | 157 |
| 13.5 | Testing by Phase..... | 160 |
| 13.6 | Team Roles | 161 |
| 13.7 | Test Documentation | 162 |

| | | |
|-----------|--|------------|
| 14 | Appendix T11 – Automated Test Execution and Computerized Test Management Tools..... | 163 |
| 14.1 | Introduction | 163 |
| 14.2 | General Benefits of Test Automation Tools | 167 |
| 14.3 | How to Use Test Automation Tools | 168 |
| 14.4 | Selection and Benchmarking of Computerized Test Tools..... | 170 |
| 14.5 | Assessment of Computerized Test Tools | 175 |
| 15 | Appendix E1 – Testing Configurable IT Systems | 179 |
| 15.1 | Introduction | 179 |
| 15.2 | What is special about these systems? – Risk Scenarios..... | 180 |
| 15.3 | Business Process versus Functional Process Testing..... | 181 |
| 15.4 | Typical Test Types and Phasing for Configurable IT Systems | 185 |
| 15.5 | Example ERP Test Script..... | 186 |
| 15.6 | Example Pharmacovigilance Test Script..... | 189 |
| 16 | Appendix E2 – Testing of Cloud Applications..... | 197 |
| 16.1 | Introduction | 197 |
| 16.2 | What is special about these systems? – Risk Scenarios..... | 199 |
| 16.3 | Typical Test Types and Phasing for Cloud Applications..... | 206 |
| 17 | Appendix E3 – Testing Analytical Instruments | 209 |
| 17.1 | Introduction | 209 |
| 17.2 | What is special about these systems? – Risk Scenarios..... | 210 |
| 17.3 | Typical Test Types and Phasing for Analytical Instruments | 213 |
| 18 | Appendix E4 – End User Developed Applications..... | 215 |
| 18.1 | Introduction | 215 |
| 18.2 | Core Package | 215 |
| 18.3 | Testing Approach | 215 |
| 18.4 | Management of Testing..... | 215 |
| 18.5 | What is special about these systems? – Risk Scenarios..... | 216 |
| 18.6 | Typical Test Types and Phasing for End User Developed Applications | 217 |
| 19 | Appendix E5 – Testing of Infrastructure and Interfaces | 219 |
| 19.1 | Introduction | 219 |
| 19.2 | What is special about these systems? – Risk Scenarios..... | 223 |
| 19.3 | Typical Test Types and Phasing for Infrastructure and Interfaces | 226 |
| 20 | Appendix E6 – Process Control Systems | 229 |
| 20.1 | Introduction | 229 |
| 20.2 | What is special about these systems? – Risk Scenarios..... | 233 |
| 20.3 | Typical Test Types and Phasing for Process Control Systems | 236 |
| 21 | Appendix E7 – Packaged Systems | 241 |
| 21.1 | Introduction | 241 |
| 21.2 | What is special about these systems? – Risk Scenarios..... | 243 |
| 21.3 | Typical Test Types and Phasing for Packaged Systems..... | 244 |
| 22 | Appendix E8 – Testing Systems Applying Process Analytical Technology..... | 249 |
| 22.1 | Introduction | 249 |
| 22.2 | What is special about these systems? – Risk Scenarios..... | 253 |
| 22.3 | Typical Test Types and Phasing for Systems Applying Process Analytical Technology..... | 257 |

| | | |
|-----------|---------------------------------------|------------|
| 23 | Appendix 20 – References | 261 |
| 24 | Appendix 21 – Glossary | 263 |
| | 24.1 Acronyms and Abbreviations | 263 |
| | 24.2 Definitions | 265 |

1 Introduction

1.1 Overview

This Guide is a revision of the first edition of the ISPE GAMP® Good Practice Guide (GPG): A Risk-Based Approach to Testing of GxP Systems. It has been updated to align with the concepts and terminology of GAMP® 5 [1], associated GAMP® guidance, and recent regulatory and industry developments. These developments focus attention on patient safety, product quality, and data integrity.

GAMP® 5 and associated GPGs aim to provide guidance to achieve computerized systems that are fit for intended use and meet current GxP regulatory requirements, by building upon existing industry good practice in an efficient and effective manner. This Guide builds on the framework described in GAMP® 5, and provides detailed guidance on testing GxP systems.

GAMP® is an ISPE Community of Practice (COP). For further information, see www.ispe.org [2].

The approach and terminology used in this Guide are generally harmonized with the following industry guidance:

- International Conference on Harmonization (ICH) Guidance including Q8 [3], Q9 [4], and Q10 [5]
- ASTM Standard E2500-07, Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment [6]
- EU GMP EudraLex Volume 4 (Chapter 4) [7] and Annex 11 [8]

This edition of the Guide also has been aligned with advances in industry best practice, including:

- Increased adoption and implementation of Process Analytical Technology (PAT) and Quality by Design (QbD)
- Increased industry focus on risk-based approaches
- Increased use of non-linear development life cycles
- Increased use of automated test tools

Consideration should be given to the existing policies and procedures within a regulated organization and to other external industry standards and practices when applying the principles described in this Guide.

1.2 Purpose

This Guide has been written to provide regulated organizations and suppliers with pragmatic guidance on the testing of computerized and software based systems that impact patient safety, product quality, and data integrity. The key objective of this Guide is to encourage regulated organizations and suppliers to work together to ensure sufficient test coverage to guarantee fitness for intended use, while minimizing any duplication of effort.

The Guide seeks to identify the testing that should be performed and the associated level of documentation. Where suppliers' systems do not meet the expectations of a regulated organization, the Guide identifies suitable risk control strategies. These strategies can include the execution of additional testing, or the selection and use of alternative suppliers or products, by the regulated organization.